FDA panel backs Merck's ragweed allergy drug Ragwitek
This article was originally published in Scrip
Executive Summary
The FDA's Allergenic Products Advisory Committee on 28 January backed Merck's ragweed allergy drug Ragwitek (MK-3641), declaring the experimental sublingual immunotherapy was safe and effective for adult use, although some on the panel questioned whether the medicine should be used in patients over 50 years because of sparse data in the older age group.